)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Autolus Therapeutics
Autolus Therapeutics (AUTL) investor relations material
Autolus Therapeutics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary11 Aug, 2026
Executive summary
Net product revenue for Q2 2026 reached $45.7 million, up 119% year-over-year and 74% sequentially from Q1 2026, driven by increased demand and expansion into new treatment centers in the US and UK.
Full-year 2026 net product revenue guidance for AUCATZYL raised to $140–$150 million, reflecting higher than expected sales momentum.
Gross margin improved to 55% in Q2 2026, up from 6% in Q1 2026 and negative in all quarters of 2025, driven by higher volumes and cost reductions.
Loss from operations narrowed to $43.8 million in Q2 2026 from $61.2 million in Q2 2025; net loss was $39.1 million, down from $47.9 million year-over-year.
Cash, cash equivalents, and marketable securities totaled $201.6 million at June 30, 2026, expected to fund operations into Q2 2028.
Financial highlights
Q2 2026 net product revenue: $45.7 million, up from $20.9 million in Q2 2025 and $26.2 million in Q1 2026.
Cost of sales decreased to $20.5 million in Q2 2026 from $24.4 million in Q2 2025; cost of sales as a percentage of revenue dropped from 117% to 45%.
R&D expenses were $27.9 million in Q2 2026 (flat vs. Q2 2025); SG&A expenses increased to $41.2 million, reflecting commercialization and restructuring costs.
Net loss for Q2 2026 was $39.1 million, improved from $47.9 million in Q2 2025.
Cash, cash equivalents, and marketable securities totaled $201.6 million as of June 30, 2026.
Outlook and guidance
FY 2026 net product revenue guidance for AUCATZYL increased to $140–$150 million from prior $120–$135 million.
Gross margin expected to improve further toward 65–70% for adult ALL over time.
Cash runway into Q2 2028, supported by $201.6 million in cash and up to $100 million from a new credit facility.
Multiple clinical data readouts expected in late 2026 through 2028, including pivotal studies in pediatric ALL, lupus nephritis, and progressive MS.
No EU product revenue anticipated in 2026 as commercial launch in Germany and other EU countries remains on hold.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Autolus Therapeutics
- Obe-cel delivers durable remissions in adult ALL, with persistence driving long-term outcomes.AUTL
Status Update - AUCATZYL's U.S. launch exceeds expectations, with expansion into Europe and autoimmune indications advancing.AUTLGoldman Sachs 46th Annual Global Healthcare Conference
- Expanding CAR T-cell therapy demonstrates robust efficacy, safety, and broadening market reach.AUTLH.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- Strong commercial growth and pipeline progress, with high remission rates and expanding indications.AUTL46th Annual William Blair Growth Stock Conference
- Lead CAR-T therapy sees robust growth, margin gains, and broadening clinical impact.AUTLJefferies Global Healthcare Conference 2026
- Strong revenue growth, clinical progress, and operational efficiency drive future value.AUTLCorporate presentation
- Q1 2026 revenue hit $26.2M, gross margin turned positive, and major cost-saving steps were taken.AUTLQ1 2026
- Obe-cel advances in B-ALL and lupus nephritis, with pivotal trials and EU/UK reviews ahead.AUTLStatus Update
- AUCATZYL's US launch drove $9M Q1 revenue, UK approval, and pivotal trials in LN and MS ahead.AUTLQ1 2025
Next Autolus Therapeutics earnings date
Q3 202611 Nov, 2026
Autolus Therapeutics
Next Autolus Therapeutics earnings date
Q3 202611 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage